FR2279422A2 - Forme pharmaceutique a base d'interferon - Google Patents

Forme pharmaceutique a base d'interferon

Info

Publication number
FR2279422A2
FR2279422A2 FR7521873A FR7521873A FR2279422A2 FR 2279422 A2 FR2279422 A2 FR 2279422A2 FR 7521873 A FR7521873 A FR 7521873A FR 7521873 A FR7521873 A FR 7521873A FR 2279422 A2 FR2279422 A2 FR 2279422A2
Authority
FR
France
Prior art keywords
esp
interferon
fixed
main linkage
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7521873A
Other languages
English (en)
Other versions
FR2279422B2 (fr
Inventor
Charles Chany
Brigitte Galliot
Marie-Josephe Chevalier
Helmut Anke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/490,658 external-priority patent/US4041152A/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of FR2279422A2 publication Critical patent/FR2279422A2/fr
Application granted granted Critical
Publication of FR2279422B2 publication Critical patent/FR2279422B2/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
FR7521873A 1974-07-22 1975-07-11 Forme pharmaceutique a base d'interferon Granted FR2279422A2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/490,658 US4041152A (en) 1973-07-27 1974-07-22 Pharmaceutical formulation of interferon insolubilized by fixation on a support

Publications (2)

Publication Number Publication Date
FR2279422A2 true FR2279422A2 (fr) 1976-02-20
FR2279422B2 FR2279422B2 (fr) 1979-08-10

Family

ID=23948962

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7521873A Granted FR2279422A2 (fr) 1974-07-22 1975-07-11 Forme pharmaceutique a base d'interferon

Country Status (1)

Country Link
FR (1) FR2279422A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989552A (en) * 1993-12-24 1999-11-23 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US8771701B2 (en) 1997-09-29 2014-07-08 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989552A (en) * 1993-12-24 1999-11-23 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US8771701B2 (en) 1997-09-29 2014-07-08 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof

Also Published As

Publication number Publication date
FR2279422B2 (fr) 1979-08-10

Similar Documents

Publication Publication Date Title
Anderson et al. Studies on uronic acid materials: Part XV. The use of molecular-sieve chromatography in studies on acacia senegal gum (Gum Arabic)
Jacobsson et al. Identification of N-sulphated disaccharide units in heparin-like polysaccharides
Goldstein et al. Interaction of concanavalin A, a phytohemagglutinin, with model substrates
ATE35418T1 (de) Oligosaccharide mit selektiver, antikoagulierender wirkung.
DK131128B (da) Fremgangsmåde til udvinding af antitrombin fra blod eller blodprodukter ved adsorption.
FR2279422A2 (fr) Forme pharmaceutique a base d'interferon
KR910011901A (ko) 난소화성 헤테로 다당류의 제조법
Bourne et al. Studies on dextrans and dextranases. 3. Structures of oligosaccharides from Leuconostoc mesenteroides (Birmingham) dextran
Kenne et al. The structure of capsular polysaccharide of the pneumococcus type II
Ukai et al. Structure of an alkali-soluble polysaccharide from the fruit body of Ganoderma japonicum Lloyd
Anderson et al. Studies on uronic acid materials. Part XVII. Some structural features of Acacia senegal gum (gum arabic)
Haug et al. Development of compositional heterogeneity in alginate degraded in homogeneous solution
Timell Isolation and properties of an O-acetyl-4-O-methylglucurono-xyloglycan from the wood of white birch (Betula papyrifera)
Kanari et al. A reticuloendothelial system-activating arabinoxylan from the bark of Cinnamomum cassia
Knirel et al. Antigenic polysaccharides of bacteria. 15. Structure of the repeating unit of O-specific polysaccharide chain of Pseudomonas wieringae lipopolysaccharide.
Yamada et al. Characterization of a water-soluble glucan from Angelica acutiloba
Leutzinger et al. The direct utilization of unsaturated sugars in nucleoside syntheses. The synthesis, configuration, and conformation of certain hex-1-enitol-3-yl, hex-2-enopyranosyl-, and hexopyranosylpurines. The preparation of 9-(1, 5-anhydro-2, 3-dideoxy-D-arabino-hex-1-enitol-3-yl) adenine and 9-(2, 3-dideoxy--D-erythro-hex-2-enopyranosyl) adenine from D-glucal
Björndal et al. Polysaccharides elaborated by Polyporus fomentarius (Fr.) and Polyporus igniarius (Fr.): Part II. water-soluble, acidic polysaccharides from the fruit bodies
NAGASAWA et al. Reaction between Carbohydrates and Sulfuric Acid. III. Depolymerization and Sulfation of Chitosan by Sulfuric Acid
Lewis et al. Structure of Leuconostoc mesenteroides strain C dextran. II. Fragmentation analysis
Wollwage et al. Acid‐catalyzed polymerization of 1, 6‐anhydro‐β‐d‐glucopyranose
Miyazaki Studies on Fungal Polysaccharides. II. On the Componental Sugars and Partial Hydrolysis of the Capsular Polysaccharide from Cryptococcus neoformans.
Majima et al. Improved analytical method for the hexuronic acids at the reducing terminals of glycosaminoglycans
Varma et al. On the carbohydrate—protein linkage group in vitreous humor hyaluronate
BJORNDAL et al. A Heterogalactan Elahorated by Polyporus squamosus